5
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Circulating Digitalis-Like Compounds in Essential Hypertension

, , , , , , & show all
Pages 441-453 | Published online: 03 Jul 2009
 

Abstract

Inhibitors of the Na+ pump have been proposed as participating in sodium excretion, xtracellular fluid regulation, and in the rise of blood pressure.

The presence of digitalis-like compounds in human plasma has been investigated by comparing the effects of plasma extracts to those of ouabain in 4 tests.

-competition with ouabain for binding to the Na+ pump

-inhibition of Na+ and K+ dependent hydrolysis

-inhibition of serotonin uptake by human platelets

-central hypertensive effect

Plasma fractions exhibited digitalis-like properties in the 4 tests. The effects of plasma extracts of 42 normotensive subjects (21 with family history of hypertension) and 38 patients with essential hypertension (15 with antihypertensive treatment) and 9 patients with chronic renal failure were compared.

Plasma from Forty per cent of untreated hypertensive patients and normotensives with hypertensive heredity had a high inhibition level. Inhibition was enhanced in beta-blocker treated patients and decreased in those on diuretics.

No digitalis-like activity was observed in uremic plasma.

These observations strongly suggest the presence of digitalis-like compound(s) in human plasma and point to its possible association with hypertension.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.